Trials / Withdrawn
WithdrawnNCT00820521
Study Evaluating Single Doses of GAP-134
Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Orally to Healthy Subjects
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of ascending single oral doses of GAP-134 in healthy subjects, to provide the initial pharmacokinetic profile of the oral formulation of GAP-134 in healthy subjects, and to evaluate the effect on the pharmacokinetic profile of a high-fat meal of 450 mg of GAP-134 administered to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | active | |
| DRUG | placebo |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2009-01-12
- Last updated
- 2018-09-27
Source: ClinicalTrials.gov record NCT00820521. Inclusion in this directory is not an endorsement.